HIF Transcription Factors, Inflammation, and Immunity  by Palazon, Asis et al.
Immunity
ReviewHIF Transcription Factors,
Inflammation, and ImmunityAsis Palazon,1 Ananda W. Goldrath,2,7 Victor Nizet,3,4,5,7 and Randall S. Johnson1,6,7,*
1Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
2Division of Biology, University of California, San Diego, La Jolla, CA 92093, USA
3Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA
4Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA
5Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093, USA
6Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm, Sweden
7Co-senior author
*Correspondence: rsj33@cam.ac.uk
http://dx.doi.org/10.1016/j.immuni.2014.09.008
The hypoxic response in cells and tissues is mediated by the family of hypoxia-inducible factor (HIF) tran-
scription factors; these play an integral role in the metabolic changes that drive cellular adaptation to low ox-
ygen availability. HIF expression and stabilization in immune cells can be triggered by hypoxia, but also by
other factors associated with pathological stress: e.g., inflammation, infectiousmicroorganisms, and cancer.
HIF induces a number of aspects of host immune function, from boosting phagocyte microbicidal capacity
to driving T cell differentiation and cytotoxic activity. Cellular metabolism is emerging as a key regulator of
immunity, and it constitutes another layer of fine-tuned immune control by HIF that can dictate myeloid
cell and lymphocyte development, fate, and function. Here we discuss how oxygen sensing in the immune
microenvironment shapes immunological response and examine how HIF and the hypoxia pathway control
innate and adaptive immunity.Introduction
Hypoxia-inducible factor (HIF) transcription factors are master
regulators of the cellular response to hypoxia and coordinate
a transcriptional program that ensures optimal functional,
metabolic, and vascular adaptation to O2 shortages (Semenza,
2011). HIF-1a is widely expressed and is detected in virtually all
innate and adaptive immune populations including macro-
phages (Cramer et al., 2003), neutrophils (Walmsley et al.,
2005), dendritic cells (Jantsch et al., 2008), and lymphocytes
(McNamee et al., 2013). HIF-2a expression is also expressed
in a range of cell types, including endothelial cells (Hu et al.,
2003) and certain immune cells. For example, HIF-2a is ex-
pressed in tumor-associated macrophages (Imtiyaz et al.,
2010; Talks et al., 2000) as well as CD8+ T cells in response
to hypoxia (Doedens et al., 2013), where its expression is
influenced by cytokine exposure. HIF-2a stabilization and
function in other immune cell types like neutrophils (Imtiyaz
et al., 2010; Thompson et al., 2014) and dendritic cells remain
largely unexplored. As has been shown in cancer cells (Holm-
quist-Mengelbier et al., 2006; Keith et al., 2012; Warnecke
et al., 2008), differing expression patterns of the HIF-1a and
HIF-2a isoforms in immune cells depend on both intrinsic and
extrinsic factors, and their resulting balance specifically con-
tributes to the regulation of overlapping or distinct sets of target
genes.
Recent work has shown that the HIF transcription factors are
key elements in the control of immune cell metabolism and func-
tion. The aim of this review is to explore how hypoxia-signaling
pathways can trigger HIF expression in the immune system,
including unique mechanisms by which immune cells stabilize
HIF, and to discuss the functional consequences for immune518 Immunity 41, October 16, 2014 ª2014 Elsevier Inc.cell function. The intent is to show how these pathways act
on immune cells in pathological states, including infection and
cancer.
The Hypoxia Pathway and Stabilization of
Hypoxia-Inducible Factor
HIF is a basic loop-helix-loop protein that forms a heterodi-
meric complex, which acts as a transcriptional regulator of
genes whose promoters contain hypoxia response consensus
sequences (HREs) (Wang et al., 1995; Wenger et al., 2005).
The regulatory complex is comprised of HIF-1b, which is
constitutively expressed, and either one of the HIF-a isoforms:
HIF-1a or HIF-2a. Additional proteins bind the complex as
coactivators and further modulate the transcription of target
genes (Arany et al., 1996). Among these direct target genes
are enzymes that control the metabolic switch for optimal
cellular adaptation to hypoxia, as well as other factors that
support organismal development and physiological adaptation
(Semenza, 2014).
HIF-a subunit stability is posttranscriptionally regulated by
oxygen availability through the iron-dependent enzymes prolyl-
hydroxylases (PHDs). When oxygen is available, PHDs are active
and hydroxylate HIF-a, marking it for proteasomal degradation in
a process mediated by von Hippel-Lindau tumor suppressor
protein (VHL)-dependent ubiquitination. If oxygen concentration
drops, PHDs become inactive, resulting in HIF-a accumulation.
Factor inhibiting HIF (FIH) provides another layer of regulation
by hydroxylating asparaginyl residues in HIF1-a and HIF-2a,
blocking protein interactions between the HIF-a transactivation
domain (CAD) and coactivators like P300 that form an effective
transcriptional complex. Apart from O2 as a cofactor, both
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Figure 1. Mechanisms of HIF Stabilization by Immune Cells
(A) O2 dependent. When oxygen is available, HIF-1a is hydroxylated by PHD, enzymes that depend on oxygen and iron as cofactors. When prolyl-hydroxylated,
HIF-1a is polyubiquitinated by VHL, marking it for proteasomal degradation. FIH hydroxylates HIF-1a at asparagine 803, which does not lead to poly-
ubiquitination, but instead blocks interactions between HIF-1a and p300/CBP, a member of the HIF complex that acts as a coactivator of target gene
transcription. When oxygen tension drops, PHD and FIH activity are inhibited, leading to HIF-1a accumulation and nuclear translocation, heterodimerization with
HIF-1b, and recruitment of p300/CBP. The HIF transcriptional complex binds to hypoxia-response elements (HREs) to control target gene expression.
(B) O2 independent. Bacterial products are recognized by TLRs expressed on myeloid cells, signaling through NF-kB to increase Hif1a transcription. In a similar
fashion, TCR ligation upon antigen presentation on T lymphocytes leads to increased Hif1a transcription and HIF-1a protein accumulation, even in the presence
of oxygen. While themechanism ofHif1amRNA induction is not known, activation of PI3K andmTOR appear to be involved in TCR-mediated induction of HIF-1a.
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limiting electron donor cosubstrate, which is oxidized and
decarboxylated to succinate. Ferrous iron and ascorbate serve
as cofactors for these hydroxylation reactions (Semenza,
2014). Inflammation, vascular injury, and compromised oxygen
availability are all hallmarks of immunological reaction to tissue
damage and infection. Limited O2 availability results in a
decrease of PHD- and FIH-dependent HIF-a hydroxylation, lead-
ing to its stabilization and nuclear translocation (Figure 1A;
Semenza, 2014).
HIF-a stabilization in immune cells can occur in an oxygen-in-
dependentmanner. Bacterial induction of HIF-1a expression has
been documented in macrophages cultured under normoxic
conditions in the presence of different pathogens (Figure 1B;
Peyssonnaux et al., 2005). Moreover, enterobacterial sidero-
phores, which are secreted high-affinity, iron-chelating agents,can lead to oxygen-independent functional HIF-1a stabilization
by limiting iron availability for optimal PHD-mediated hydroxyl-
ation (Hartmann et al., 2008). Lipopolysaccharide (LPS), a major
cell membrane component of Gram-negative bacteria, induces
HIF-1a protein accumulation in macrophages through transcrip-
tional and translational activation, acting independently from
hypoxia-induced HIF-1a protein stabilization (Blouin et al.,
2004). Nuclear factor-kB (NF-kB), which plays a central role in
regulating the immune response to infection, is also required
for the bacteria-induced HIF-1a mRNA transcriptional response
in macrophages (Rius et al., 2008). Tumor necrosis factor-a
(TNF-a), another key host inflammatory mediator, can induce
HIF-1a expression in macrophages harvested from wounds
and cultured under normoxic conditions (Albina et al., 2001),
providing another link between inflammation and HIF stabiliza-
tion in immune cells. Oxidized low-density lipoprotein, whichImmunity 41, October 16, 2014 ª2014 Elsevier Inc. 519
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also leads to HIF-1a protein accumulation in human macro-
phages through a mechanism involving reactive oxygen species
(ROS) (Shatrov et al., 2003). Similar to macrophages, ROS pro-
duction by activated T cells (Sena et al., 2013) may constitute
another mechanism of HIF induction. ROS can drive HIF-1a
transcription and function by either activating the HIF-1a pro-
moter (Bonello et al., 2007) or regulating hydroxylase function,
especially that of the asparaginyl hydroxylase FIH (Masson
et al., 2012).
Adaptive immune cells can also stabilize HIF-1a through oxy-
gen-independent mechanisms (Figure 1B). T cell receptor (TCR)
ligation induces substantial accumulation of HIF-1a mRNA and
protein, especially in the proinflammatory T helper 17 (Th17)
CD4+ T cell lineage, by a mechanism dependent on STAT3
(Dang et al., 2011; Ikejiri et al., 2012; Nakamura et al., 2005;
Shi et al., 2011; Wang et al., 2014), where IL-6 and transforming
growth factor-b (TGF-b) enhance HIF-1a mRNA expression via
a signal transduction and activator of transcription (STAT3)-
dependent mechanism (Dang et al., 2011; Kojima et al., 2002;
Shi et al., 2011). In contrast, stimulation of CD4+ T cells differen-
tiated with cytokines promoting other helper subsets showed
minimal increases in HIF-1a mRNA or protein upon activation
(Dang et al., 2011; Shi et al., 2011). CD8+ T cells also rapidly sta-
bilize HIF-1a and HIF-2a proteins upon in vitro TCR crosslinking
in normoxic conditions (Doedens et al., 2013; Finlay et al., 2012;
Wang et al., 2011). Further, interleukin-4 (IL-4), which induces
HIF-2a stabilization in macrophages (Takeda et al., 2010),
also contributes to HIF-2a accumulation in activated CD8+
T cells, while IL-2 conditions favor HIF-1a accumulation (Doe-
dens et al., 2013). Thus, HIF is positioned to be a key player in
the integration of TCR- and cytokine receptor-mediated signals
involved in CD4+ helper lineage commitment and CD8+ effector
differentiation in a fashion independent of oxygen availability.
This suggests a potential role for HIF-1a in promoting T-cell-
mediated inflammation and indicates that microenvironmental
cues and cytokines that drive T cell fate and differentiation are
also crucial in shaping the hypoxia response in T cells.
HIF and Innate Immunity
Inflammation
Monocyte and neutrophil development and differentiation are
not affected by specific deletion of HIF-1a in themyeloid lineage,
as shown by conditional gene targeting (Cramer et al., 2003). In
contrast, mice with HIF-1a myeloid-specific deletion showed
impaired inflammatory responses, which are linked to a meta-
bolic defect characterized by lower glycolytic rates and energy
generation when HIF-1a is absent. As a result, macrophages
show impaired aggregation, invasion, and motility. Notably,
myeloid HIF-1a contributes to inflammation in rheumatoid
arthritis synovial tissue (Cramer et al., 2003), which is hypoxic
(Konisti et al., 2012).
Indeed, the relationship between the hypoxic and inflamma-
tory responses is tightly controlled (Figure 2A). As noted above,
hypoxia and bacterial infections result in increased nuclear fac-
tor-kappa B (NF-kB) activity in phagocytes, which in turn induces
HIF-1a mRNA transcription (Cummins et al., 2006; Fitzpatrick
et al., 2011; Rius et al., 2008). Together with NF-kB, the p42/
p44 mitogen-activated protein kinase (MAPK) (Erk) pathway is520 Immunity 41, October 16, 2014 ª2014 Elsevier Inc.involved in LPS-induced HIF-1a induction in human monocytes
(Frede et al., 2006).
Neutrophils are short-lived innate immune cells that contribute
to the inflammatory response. Hypoxia delays neutrophil
apoptosis in a reversible manner, through a process that can
be mimicked by iron chelator agents (Mecklenburgh et al.,
2002). In fact, hypoxia induces neutrophil survival through HIF-
1a-dependent NF-kB activity that results in sustained inflamma-
tion (Walmsley et al., 2005). FIH, PHD1, and PHD2 protein
expression in neutrophils are not affected by hypoxia (Walmsley
et al., 2005). However, PHD3 expression is increased in neutro-
phils subjected to hypoxia or isolated from rheumatoid arthritis
patients (Walmsley et al., 2011). Selective ablation of PHD3 in
neutrophils abrogates this hypoxic prosurvival effect and re-
duces neutrophilic inflammation in a colitis model, revealing a
tight control by the hypoxia pathway (Walmsley et al., 2011).
Thus, HIF-1a-induced NF-kB controls neutrophil proinflamma-
tory functions and survival under hypoxia, which requires
PHD3 expression. In similar fashion, neutrophil accumulation in
a mouse model of colitis induced an inflammatory hypoxic
microenvironment that favored resolution, which was abrogated
when neutrophils were depleted or lacked respiratory burst, but
restored upon pharmacological HIF-1a stabilization (Campbell
et al., 2014).
HIF-2a also regulates essential inflammatory functions of
immune cells. Mice lacking HIF-2a in the myeloid compartment
fail to mount an inflammatory response upon LPS challenge,
due to impaired tumor necrosis factor-a (TNF-a), interferon-g
(IFN-g), IL-12, and IL-1b production. In contrast to proinflamma-
tory cytokine expression, HIF-2a was not found to control nitric
oxide (NO) production or alter macrophage activation marker
expression (Imtiyaz et al., 2010). Although this study and others
(Mecklenburgh et al., 2002; Walmsley et al., 2005) fail to detect
HIF-2a mRNA or protein in bone marrow-derived neutrophils, a
recent publication highlights that hypoxia, hydroxylase inhibi-
tion, and bacteria can induce HIF-2a expression in human and
murine peripheral blood neutrophils (Thompson et al., 2014).
Mice lacking myeloid HIF-2a have reduced neutrophilic inflam-
mation and increased neutrophil apoptosis. Neutrophils isolated
from arthritis patients also express increased amounts of HIF-2a
protein (Thompson et al., 2014).
The identification of the involvement of the hypoxia pathway in
proinflammatory responses has supported efforts to develop
novel therapeutic approaches to treat inflammatory disorders.
In this regard, HIF-1a inhibition could be a potential strategy
for limiting exacerbated responses, such as arthritis (Giaccia
et al., 2003). Another approach consists of PHD inhibition, which
has shown therapeutic potential in preclinical models of colitis
(Cummins et al., 2008; Fraisl et al., 2009; Robinson et al., 2008).
Bacterial Infection
Since bacterial infection typically results in a hypoxic tissue
microenvironment, in vivo models of infection have made an
important contribution to our understanding of the role of the
hypoxia pathway in innate immune cells called upon to fight
pathogens.
HIF-1a-deficient macrophages have an impaired metabolic
adaptation tohypoxia,which results in reducedmotilityandmigra-
tion. Moreover, HIF-1a-deficient macrophages show decreased
capacity to kill bacteria. Although the rate of phagocytic uptake
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Figure 2. Hypoxia Pathway and Innate Immunity
(A) Inflammation. HIF-1a and NF-kB crosstalk regulates essential inflammatory functions in myeloid cells. HIF-1a increases macrophage aggregation, invasion,
and motility and drives the expression of proinflammatory cytokines. HIF-1a also increases neutrophil survival by inhibiting apoptosis and triggers NF-kB-
dependent neutrophilic inflammation.
(B) Infection. HIF-1a increases intracellular bacterial killing by macrophages and also promotes granule protease production and release of nitric oxide (NO) and
TNF-a, which in turn further contribute in antimicrobial control.
(C) Metabolism. HIF-1a in myeloid cells increases the transcription of key glycolytic enzymes, resulting on increased glucose uptake and glycolytic rate.
Importantly, pyruvate entry in the citric acid cycle (TCA) is inhibited and converted to lactate, which is released to the extracellular compartment. This metabolic
adaptation results in a decreasedO2 consumption by limiting the rate of oxidative phosphorylation (OXPHOS). M1 andM2 polarizedmacrophages show different
metabolic pathway preferences: whereas M1 rely on glycolysis as energy source, M2 have steady OXPHOS metabolism.
(D) Cancer. As a result of hypoxia, HIF-1a is stabilized in cancer cells, increasing the production of chemotactic factors like CCL5, CXCL12, VEGF, endothelins
ET-1 and ET-2, and semaphorin3A (Sema3A), which result in myeloid cell recruitment to the tumor. Once located in hypoxic regions, tumor-associated mac-
rophages stabilize HIF-1a, which contributes to tumor-promoting inflammation, angiogenesis, and impaired lymphocyte function.
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is severely impaired when HIF-1a is genetically ablated (Cramer
et al., 2003). Other studies using different pathogens have pointed
to a potential role of hypoxia and HIF-1a in the control of bacterial
phagocytosis (Figure 2B; Anand et al., 2007).
A subsequent study using HIF-1a conditional gene targeting
in myeloid cells confirmed that both hypoxia and HIF-1a regu-
late the intracellular killing by macrophages infected with
group A Streptococcus (GAS) and Pseudomonas aeruginosa.
Conversely, VHL-deficient macrophages showed enhanced
bactericidal capacity (Peyssonnaux et al., 2005). In vivo experi-
ments indicated that mice were more susceptible to GAS infec-tion when lacking myeloid HIF-1a, resulting in more severe
necrotic skin ulcers and greater weight loss. In these studies
HIF-1a was correlated with iNOS expression, driving NO and
TNF-a production; these in turn have an important role in regu-
lating the antimicrobial action of myeloid cells (Peyssonnaux
et al., 2005). In similar fashion, neutrophil bactericidal activity is
controlled by HIF-1a. Although HIF-1a-deficient neutrophils
migrate to GAS-induced skin lesions at similar rates compared
to their HIF-1a-competent counterparts, they present markedly
decreased production of granule proteases and cathelicidin
antimicrobial peptide (Peyssonnaux et al., 2005). Moreover,
neutrophils isolated from patients with heterozygous germlineImmunity 41, October 16, 2014 ª2014 Elsevier Inc. 521
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cocci (Walmsley et al., 2006). Exploiting these relationships,
pharmacological stabilization of HIF-1a enhanced phagocyte-
mediated clearance of methicillin-resistant Staphylococcus
aureus in vitro and in vivo (Okumura et al., 2012).
Macrophage Metabolism and Polarization
An emerging topic is the control of myeloid cell function bymeta-
bolic activity. As we have discussed, the environmental milieu
promotes HIF-1a expression in myeloid cells fighting against
pathogens or cancer, driving a metabolic shift to modulate oxy-
gen consumption and energy choices. Macrophages undergo-
ing LPS-induced M1 polarization have a robust metabolic shift
toward glycolysis, pentose-phosphate pathway activity, and
basal oxidative phosphorylation, whereas immunomodulatory
IL-4-induced M2-like macrophages have moderate glycolytic
activity but higher oxidative activity (Figure 2C; Haschemi
et al., 2012). This work underlines the importance of metabolic
reprogramming in themacrophage response tomicrobial stimuli.
Determining the extent to which the hypoxia pathway links
myeloid metabolic adaptation with inflammatory response is an
exciting field of new investigation.
HIF-2a is known to have a more discrete role in the glyco-
lytic adaptation to hypoxia in cancer cells (Hu et al., 2003) and
macrophages (Imtiyaz et al., 2010). Although arginase has an
important role in the HIF-2a contribution to IL-4-induced M2
polarization, the fact that HIF-2a is selectively induced in M2-
like macrophages (Takeda et al., 2010) could indicate a potential
metabolic mechanism by which increased expression of HIF-2a
outcompete HIF-1a in its transcriptional activity, limiting the
glycolytic shift associated to M1 polarization. However, it is still
not clear whethermetabolic adaptation is cause or consequence
of the myeloid cellular differentiation program in inflammatory
responses. Moreover, HIF-1a can also drive immunosuppres-
sive functions by myeloid cells, i.e., inducible NO synthase
(iNOS) production (Peyssonnaux et al., 2005), and macrophages
lacking HIF-2a fail to mount an inflammatory response upon LPS
challenge (Imtiyaz et al., 2010), indicating that the different
functions of the HIF isoforms on macrophage polarization are
not completely exclusive, but sometimes overlapping and
dependent on the pathophysiological context.
Viral Infection
HIF-1a activity is induced in response to viral infection, but accu-
mulating evidence suggests that the net consequence can favor
the pathogen rather than the host. In particular, certain viruses
have evolved mechanisms to stabilize HIF-1a to exert an antia-
poptotic effect that promotes survival of the infected cell. Hepati-
tis B HBx protein increases HIF-1a transactivation by enhancing
its association with cAMP-response element binding protein
(CREB)-binding protein (BP) (Yoo et al., 2003). Kaposi’s sar-
coma-associatedherpesvirus (KSHV) latency-associated nuclear
antigen (LANA) targets VHL for degradation via ubiquitination,
increasing HIF protein expression (Cai et al., 2006) and Epstein-
Barr virus (EBV) oncoprotein LMP1 boostsHIF-1a concentrations
by increasing the proteasomal degradation of PHD1 and PHD3
that normally mark HIF-1a for degradation (Kondo et al., 2006).
In HIV-1 and JCV polyomavirus infection, HIF-1a directly stimu-
lates the transcription of key viral HIV-1 genes by associating
with the HIV-1 long terminal repeat (Deshmane et al., 2009) or
JCV early promoter (Pin˜a-Oviedo et al., 2009), respectively.522 Immunity 41, October 16, 2014 ª2014 Elsevier Inc.Dendritic Cells and Antigen Presentation
The function and in vivo relevance of HIF-1a in dendritic cells
(DCs) are still not completely clear. HIF-1a stabilization does
not affect DC maturation in the absence of proinflammatory
stimuli (Elia et al., 2008). LPS-treated human monocyte-derived
DCs cultured under hypoxia express lower amounts of costimu-
latory molecules and maturation markers, resulting in decreased
T cell proliferation upon antigen presentation. In contrast,
hypoxia induces the production of proinflammatory cytokines
(TNF-a, IL-1b) by DCs (Mancino et al., 2008), modulates chemo-
kine receptor expression (Ricciardi et al., 2008), and decreases
DC migration in response to C-C chemokine receptor type 7
(CCR7) ligands (Mancino et al., 2008; Qu et al., 2005; Zhao
et al., 2005).
Upon toll-like receptor (TLR) ligation, DCs stabilize HIF-1a
(Jantsch et al., 2011) and undergo a metabolic shift similar to
that observed in other activated and hypoxic immune cells,
relying on aerobic glycolysis to support maturation and func-
tion (Jantsch et al., 2008; Krawczyk et al., 2010). Pharmacolog-
ical HIF-1a stabilization with a PHD inhibitor increased major
histocompatibility complex (MHC) and costimulatory molecule
expression by DCs, which in turn induced greater T cell prolifer-
ation, serving to produce higher titers of antibodies on immuniza-
tion with the model antigen ovalbumin (Bhandari et al., 2013).
However, the role of the hypoxia pathway in this process is still
to be fully determined, and robust in vivomodels and experimen-
tation are needed to ascertain whether HIF-1a could affect anti-
gen presentation, key for the crosstalk between the innate and
adaptive immune system.
Innate Immunity and Cancer
Myeloid cells are a prominent population infiltrating solid tumors.
Macrophages are recruited into tumors, and although they have
the ability to inhibit angiogenesis and fight malignant progres-
sion, they are commonly associated with a microenvironment
that predisposes to tumor immune escape, new vessel forma-
tion, and metastasis (Figure 2D).
Hypoxia, as a prominent feature of solid tumors, leads to HIF-
1a stabilization in cancer cells and contributes to the recruitment
of bone-marrow-derived myeloid cells by at least two key mech-
anisms. First, HIF-1a drives the production of chemokines and
chemokine receptors that could influence myeloid recruitment
(Murdoch et al., 2004). For instance, CCL5 and C-X-C motif
chemokine 12 (CXCL12, also known as SDF1a) production by
hypoxic tumor cells is driven by HIF-1a (Du et al., 2008; Lin
et al., 2012), and chemokine receptor C-X-Cmotif chemokine re-
ceptor (CXCR4) expression by myeloid and tumor cells is regu-
lated by the VHL-HIF axis (Schioppa et al., 2003; Staller et al.,
2003). Second, HIF-1a in tumor cells increases the secretion of
cytokines, mainly VEGF, which can act as a chemoattractant
for myeloid cells (Leek et al., 2000), an effect that is dependent
on VEGF receptor 2 (VEGFR2) expression on macrophages
(Dineen et al., 2008). Endothelins ET-1 and ET-2 are also chemo-
attractants for monocyte/macrophage recruitment into tumors,
and their expression by tumor cells is induced by HIF-1a (Grim-
shaw, 2007; Grimshaw et al., 2002).
Hypoxia-induced tumor-produced semaphorin3A (Sema3A)
also contributes to recruitment of macrophages into hypoxic
tumors by binding neuropilin-1 (Nrp-1) and PlexinA1/A4 core-
ceptors and signaling through VEGFR1. When macrophages
Immunity
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A4 is repressed by hypoxia, leading to tumor-associated macro-
phage (TAM) accumulation. Deletion of Nrp-1 on macrophages
prevents TAM infiltration in hypoxic regions, resulting in delayed
tumor growth, which is in turn characterized by impaired vascu-
larization and improved antitumor immunity (Casazza et al.,
2013).
Once recruited, the influence of different factors present in the
tumor microenvironment results in different TAM phenotypes,
which can be classified into different subsets. For instance,
TAMs infiltrating hypoxic tumor regions have been associated
with an increased and proangiogenic M2-like phenotype, char-
acterized by lower MHC-II expression compared to TAMs
located in normoxic areas (Laoui et al., 2014; Movahedi et al.,
2010).
TAMs contribute to tumor-promoting chronic inflammation in
part by directly dampening adaptive immunity, as well as by
secreting extracellular factors that fuel endothelial andmalignant
cell proliferation and survival. Targeted deletion of HIF-1a in
macrophages resulted in reduced tumor growth in a sponta-
neous PYMT mammary adenocarcinoma model, which was
shown to result from improved lymphocyte proliferative capacity
and function when myeloid HIF-1a is absent (Doedens et al.,
2010; Lewis and Murdoch, 2005). Myeloid-derived suppressor
cells are another stromal component that can dampen antitumor
immunity, and HIF-1a can modulate their function and differenti-
ation into tumor-associated macrophages (Corzo et al., 2010)
and their expression of the immune checkpoint ligand PD-L1
(Noman et al., 2014).
Macrophages can promote angiogenesis (Lin et al., 2006).
Tie2-expressingmonocytes are considered an important lineage
that contributes to tumor vascularization (De Palma et al., 2005)
and Tie2 expression in this population is regulated by hypoxia,
which could contribute to its recruitment and function (Lewis
et al., 2007).
VEGF is the most studied endothelial-mitogen among macro-
phage-secreted factors modulated by hypoxia (Shweiki et al.,
1992), and its induction in myeloid cells is driven by HIF-1a
(Cramer et al., 2003; Eubank et al., 2011; Roda et al., 2012).
The contribution of macrophage-derived VEGF to angiogenesis
and malignancy has been studied in a variety of tumor models
(Stockmann et al., 2008). Upon macrophage depletion, delayed
mammary carcinoma progression can be restored by VEGF (Lin
et al., 2007).
Although it is accepted that VEGF contributes to tumorigen-
esis (Goel and Mercurio, 2013), when VEGF is specifically
deleted in the myeloid lineage, spontaneous mammary PYMT
tumors developed faster, as a result of blockade of the angio-
genic switch and vascular normalization (Stockmann et al.,
2008). This study highlighted the multifaceted aspects of TAMs
and TAM-derived VEGF on tumor progression, and suggested
that separate from total VEGF expression in tumors, myeloid-
derived VEGF could fine-tune angiogenesis upon endothelial-
macrophage interactions.
Hypoxic TAMs can also contribute to increased VEGF bio-
availability by releasing MMP-9, a matrix metalloproteinase
induced by HIF-1a, resulting in increased neovascularization
and tumor cell invasiveness (Du et al., 2008). On the other
hand, primary tumor-released VEGF can induce MMP-9 onmacrophages present in the premetastatic niche, promoting
metastasis (Hiratsuka et al., 2002). HIF-1a signaling in primary
mammary tumors leads to the induction of members of the
lysyl oxidase (LOX) family, preconditioning the lungs for bone-
marrow-derived cell recruitment prior to metastatic colonization
(Wong et al., 2011).
HIF-2a is also expressed in TAMs. Absence of HIF-2a impairs
infiltration, migration, and chemotactic receptor expression by
TAMs, resulting in reduced inflammatory murine-associated
cancer (Imtiyaz et al., 2010). In contrast to HIF-1a, HIF-2a does
not control the hypoxic induction of VEGF in macrophages
(Ahn et al., 2014; Eubank et al., 2011), but it can induce soluble
VEGF receptor 1 (sVEGFR-1) secretion by hypoxic macro-
phages, which neutralizes VEGF (Roda et al., 2011) and raises
another potential opposing role for different HIF isoforms.
HIF and Adaptive Immunity
In the process of T cell development, lymphoid progenitors
migrate from the bone marrow to the thymus, an organ known
to be hypoxic under physiological conditions (Hale et al.,
2002). T cell precursors that lack CD4 or CD8 coreceptor surface
expression initiate TCR rearrangements and navigate multiple
developmental checkpoints and selection events that coordi-
nate MHC restriction and functional activity with lineage before
becoming mature gd or ab CD4+ and CD8+ T cells that migrate
to peripheral lymphoid tissues. In contrast to myeloid VHL
deletion, which does not affect neutrophil and monocyte devel-
opment (Cramer et al., 2003), specific deletion of VHL in thymo-
cytes early in development by a cre recombinase expressed
under the control of the proximal Lck promoter resulted in a
dramatic reduction in thymic cellularity. Additional deletion of
HIF-1a with VHL deficiency restored thymocyte development
and prevented excessive apoptosis associated with VHL dele-
tion (Biju et al., 2004), suggesting a tightly regulated role of the
hypoxia pathway in lymphocyte development. On the other
hand, loss of HIF-1a does not obviously impact thymic subsets
or CD4+ and CD8+ T cells in secondary lymphoid organs (Kojima
et al., 2002). However, HIF-1a deficiency in the lymphoid
compartment does result in abnormal B cell development and
autoimmunity (Kojima et al., 2002); interestingly, CD19-cre-medi-
ated B cell-specific deletion prevents hypoxic cell cycle arrest in
B cells, an indication of HIF-1a’s importance in lymphoid cell
homeostasis (Goda et al., 2003).
Given the substantial induction of HIF-1amRNA and protein in
response to T cell activation and the well-known role of HIF in
driving glycolytic metabolism, several groups have recently
explored potential HIF function in adaptive immune responses.
How HIF activity impacts T cell activation and differentiation is
a timely topic because it is now also thought that changes in
metabolic activity not only accompany the dramatic expansion
and acquisition of effector function driven by recognition of
antigen, but may also be intimately involved in fate decisions
of differentiating effector cells. Proinflammatory Th1, Th2, and
Th17 cell populations generated in vitro display increased glycol-
ysis and less OXPHOS than in-vitro-induced T regulatory cells,
which show a greater reliance on lipid oxidation and OXPHOS
(Michalek et al., 2011; Shi et al., 2011). Consistent with HIF’s
role in promoting glycolysis, HIF-1a is highly expressed by
Th17 cells. Deletion of HIF-1a in T cells impairs differentiationImmunity 41, October 16, 2014 ª2014 Elsevier Inc. 523
A B Figure 3. Hypoxia Pathway and Adaptive
Immunity
(A) T cell differentiation. Upon activation, HIF-1a is
strongly induced in conditions that favor differen-
tiation of CD4+ Th17 cells. HIF-1a can increase the
expression of RORgt, which in turn promotes IL-
17 production and Th17 cell development. Th17
and Treg cells also rely on different metabolic
pathways. HIF-1a can bind FOXP3 protein and
impact its function and degradation, and in some
cases, promotes Foxp3 mRNA induction and
supports Treg cell function. HIF-1a-driven glyco-
lytic shift supports Th17 cell differentiation, while
lack of HIF-1a can support Treg cell differentiation
under Th17 cell differentiation conditions.
(B) HIF-1a stabilization by activated CD8+ T cells
results in increased expression and release of important cytolytic molecules (granzyme B, perforin), increased expression of costimulatory/inhibitory molecules
(CTLA-4, GITR, 4-1BB), and altered migration and chemokine receptor expression.
Immunity
Reviewof CD4+ Th17 producing cells in vitro and in MOG/CFA-induced
experimental autoimmune encephalomyelitis (EAE) (Dang et al.,
2011; Shi et al., 2011). Inversely, hypoxia and deletion of VHL or
miR-210, which also promote stabilization of HIF-1a, can
enhance generation of Th17 CD4+ cells (Dang et al., 2011; Ikejiri
et al., 2012; Wang et al., 2014). The inhibition of glycolysis, in
turn, reduces Th17 cell induction and protects from EAE, sug-
gesting that HIF regulation of metabolic activity underlies its
role in T helper cell subset differentiation (Shi et al., 2011). How-
ever, HIF-1a also may favor the Th17 cell lineage by directly
promoting expression of RORgt (RAR-related orphan receptor
gt) and its target IL-17 (Dang et al., 2011).
The generation of regulatory T (Treg) cells in the peripheral im-
mune compartment is entwined with induction of Th17 CD4+
cells, as both rely on TGF-b, which can in turn promote expres-
sion of both RORgt and FOXP3; these latter are key transcription
factors regulating the development of each respective cell
type (Littman and Rudensky, 2010). Forkhead binding protein 3
(FOXP3) antagonizes RORgt, unless IL-6 is present to drive
Th17 cell development; thus, the generation of these two line-
ages is linked to the inflammatory milieu and is generally recip-
rocal. Consistent with HIF-1a promoting Th17 cell formation,
these groups also observed enhanced Treg cell differentiation
with deletion of HIF-1a in conditions favoring Th17 cells (Clam-
bey et al., 2012; Dang et al., 2011; Shi et al., 2011); inhibition of
glycolysis had the same effect (Shi et al., 2011). One proposed
mechanism for HIF attenuation of Treg cell development is direct
binding and targeting of FOXP3 for degradation (Dang et al.,
2011; Darce et al., 2012). However, in conditions promoting
Treg cell induction, hypoxia can enhance FOXP3 expression
and Treg cell accumulation, and in vivo HIF-1a-deficient Treg
cells display impaired suppressive function in T-cell-mediated
colitis (Clambey et al., 2012). Thus, hypoxia and HIF activity
may regulate CD4+ T cell differentiation differently in divergent
tissue microenvironments (Figure 3A).
HIF-1a can also drive metabolic adaptations in CD8+ T cells
and control expression of many molecules associated with
effector function and migration (Doedens et al., 2013; Finlay
et al., 2012). The earliest phases of activation-induced metabolic
reprogramming appear to be Myc dependent, as HIF-deficient
T cells induce glycolysis (Wang et al., 2011). However, as
CD8+ T cells differentiate to effector cells, loss of HIF-1b impairs
expression of genes controlling glycolysis and glycolytic capac-524 Immunity 41, October 16, 2014 ª2014 Elsevier Inc.ity, albeit not completely (Finlay et al., 2012). Interestingly, HIF-
1b-deficient T cells show diminished expression of effector mol-
ecules, such as perforin and granzymes, and altered expression
of molecules involved in T cell migratory capacity. HIF-1b-defi-
cient CD8+ T cells maintained CD62L expression in conditions
where wild-type cells lost CD62L, yet displayed increased
T cell homing to secondary lymphoid organs, perhaps due to
aberrant upregulation of CXCR5, CCR7, and S1P1R (Finlay
et al., 2012). This study and others establish HIF and glycolysis
downstream of the mechanistic target of rapamycin (mTOR),
coupling induction of HIF-1a with metabolic changes and regu-
lation of CD8+ effector cell function and trafficking (Figure 3B;
Finlay et al., 2012; Nakamura et al., 2005; Shi et al., 2011).
Enhanced HIF activity resulting from deletion of VHL promotes
glycolytic metabolism and effector function by CD8+ T cells
(Doedens et al., 2013), further highlighting a role for HIF in host
protection. Hypoxia, via a HIF-dependent mechanism, induces
expression of many key T cell activation receptors (4-1BB,
glucocorticoid-induced TNFR family related gene [GITR],
OX40), inhibitory receptors (lymphocyte activation gene-3
[LAG-3], cytotoxic T-lymphocyte-associated protein 4 [CTLA-
4]), and effector molecules (Granzyme B), while suppressing
expression of key transcription factors (T-bet, Eomes, TCF-1)
in CD8+ effector cells. VHL-deficient T cells are potent effectors,
clearing virus and slowing tumor growth when wild-type CD8+
T cells lose effector function and undergo progressive ‘‘exhaus-
tion’’ due to chronic antigen exposure. Stabilization of HIF in
CD8+ T cells apparently can bypass inhibitory receptor signaling
typically associated with the dampening of effector capacity
when antigen cannot be cleared. However, the exhaustion-
induced loss of function by CD8+ T cells serves to limit immuno-
pathology in persistent infections, and the exuberant response of
VHL-deficient T cells also mediates host death when mice are
infected with a strain of virus that cannot be efficiently cleared
by the immune system. Thus, manipulation of HIF activity in
CD8+ T cells may serve to exacerbate or avert immunopa-
thology, promote pathogen clearance, or diminish tumor burden,
depending on the context.
Adaptive Immunity and Cancer
In the context of cancer immunology, tumor-infiltrating lympho-
cytes (TILs) comprise a heterogeneous population. CD4+ Th1
cells and CD8+ cytotoxic lymphocytes have been generally
linked to a better prognosis in cancer patients (Tosolini et al.,
Immunity
Review2011). On the other hand, T regulatory cells that suppress
self-reactive T cells, protecting the host from autoimmunity,
can be deleterious in mounting an effective antitumor immune
response; indeed, high numbers of Treg cells and low CD8+
T cell:Treg cell ratios have been associated with a worse prog-
nosis (Sato et al., 2005). Although solid malignancies are oxygen
deprived due to an imbalance between vascularization and
cellular demands, it is not known how hypoxia signaling in TILs
affects migration, survival, crosstalk, and immune function of
both effector and suppressive cells.
The effects of HIF signaling in cancer cells are better estab-
lished and lead to invasion, angiogenesis, metastasis, and
secretion of tumor-derived factors like cytokines and growth
factors that recruit immunosuppressive cells. As previously dis-
cussed, intratumoral hypoxia and HIF-1a stabilization in cancer
cells and stromal components such as endothelial cells and
TAMs induce VEGF secretion. VEGF acts as a Treg cell chemo-
tactic factor by binding to Neuropilin-1 (NP-1). Mice deficient in
T-cell-specific NP-1 have impaired infiltration of Treg cell into
tumors, which results in impaired melanoma tumor growth (Han-
sen et al., 2012). HIF-1a can also promote TGF-b secretion by
cancer cells (Deng et al., 2013). TGF-b, itself a critical modulator
of inflammation, acts as an important chemo-attractant for Treg
cell recruitment into tumors and can also bind NP-1 (Glinka and
Prud’homme, 2008). CCL28 is another chemokine that is
secreted by hypoxic tumor cells and attracts CXCR10+ Treg cells
to the tumor site, promoting tumor tolerance and angiogenesis
(Facciabene et al., 2011). In addition, an increase in the intratu-
moral pool of adenosine as a result of hypoxia has been pro-
posed as an immune-tolerance mechanism (Sitkovsky and
Lukashev, 2005).
Another contribution of hypoxia to tumor immune escape that
is mediated by HIF-1a is a decrease in cancer cell susceptibility
to T-cell-mediated killing (Noman et al., 2009). Hypoxia also in-
duces tumor cell autophagy, a process that confers resistance
to immune-mediated lysis by cytotoxic lymphocytes (Noman
et al., 2011) and natural killer (NK) cells (Baginska et al., 2013).
Programmed cell death 1 (PD-1) and CTLA-4 act as coinhibitory
receptors on activated T cells and are important targets for
cancer immunotherapy strategies based on the administration
of blocking antibodies. HIF-1a drives CTLA-4 expression on
CD8+ T cells (Doedens et al., 2013) and HIF-1a also increases
PD-L1 expression on hypoxic cancer cells to promote immune
escape (Barsoum et al., 2014). HIF-1a has also been shown
to upregulate other costimulatory receptors that are potential
targets for cancer immunotherapy: OX40, GITR, and 4-1BB
(Doedens et al., 2013; Palazo´n et al., 2011, 2012).
An increasing number of agents aiming to inhibit HIF-1a are
under development for cancer treatment (Onnis et al., 2009).
Given the cellular heterogeneity in the tumor microenvironment,
and the fact that the contribution of HIF to malignant and stromal
cell populations could differentially drive tumor progression,
ongoing early clinical trials will help to understand the impact
of HIF inhibition and other novel agents targeting the hypoxia
pathway in terms of immune control and cancer progression.
As a result, new rational therapeutic combinations targeting
hypoxia and angiogenesis (Rapisarda and Melillo, 2012) or novel
immunotherapies (Mellman et al., 2011) could help to overcome
the multiple mechanisms of tumor resistance.Concluding Remarks
Recent research has highlighted the importance of hypoxic
response and HIF signaling in controlling immune responses.
Although HIF-1a is considered central in the control of the
response, emerging data support the notion that HIF-2a can
exert different and sometimes opposing roles. All of these results
are in part a demonstration of the critical nature of the tissue
microenvironment in immunity.
All immune cells are present in a physiologically complex and
fluctuating tissue environment, whereby pH, oxygen, nutrients,
and metabolites are both in and out of homeostatic balance
relative to each other and to the ‘‘normal’’ environment of that
immune cell. Add to the equation the physiological chaos of a
virulent infection or a necrotic tumor, and the need to understand
the relationship between immunological function and immune
cell response to this flux becomes central to understanding the
immune response. As the analysis of immunophysiology be-
comes more sophisticated, the opportunities for development
of relevant and effective immunotherapies can only continue to
expand.
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